Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTREPID-1: Oprozomib formulations in RRMM
NCT02939183Phase 1Completed
- Sponsor
- Amgen
- Start
- Jan 2017
- Primary completion
- Oct 2022
- Modality
- Irreversible Covalent Inhibitors
- Countries
- 4
01
Overview
Phase 1, open-label trial of oprozomib in multiple myeloma (MM) (5 arms), sponsored by Amgen. Primary endpoints: Dose-Limiting Toxicity, Maximum Tolerated Dose and 1 more. Started Jan 2017; status: completed.
02
Drugs
oprozomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02939183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02939183.